We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genincode Plc | LSE:GENI | London | Ordinary Share | GB00BL97B504 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.13 | 14.29% | 9.00 | 8.50 | 9.50 | 9.00 | 8.00 | 8.00 | 182,888 | 16:18:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 1.43M | -5.56M | -0.0580 | -1.55 | 8.62M |
From May 2021 to May 2024
By Kyle Morris
GENinCode PLC said Monday that it has filed its pre-submission for Cardio inCode-SCORE with the U.S. Food and Drug Administration.
The predictive genetics company said that it had been invited by the FDA to file the pre-submission and this marks the start of the regulatory pathway for U.S. market approval, anticipated later this year.
Cardio inCode-SCORE is an in-vitro diagnostic test that assesses the combined genetic and clinical risk of cardiovascular disease, it said.
Shares in GENinCode at 1022 GMT trade up 0.5 pence, or 1.6%, at 32.5 pence.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
January 10, 2022 05:47 ET (10:47 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Genincode Chart |
1 Month Genincode Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
